Collegium Pharmaceutical, Inc.
COLL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $2 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 11.4% | 5.8% | -2.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 61.7% | 57.7% | 54.8% | 54% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 58.1% | 50.1% | 45.3% | 53% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 15% | 6.4% | 1.4% | 6.9% |
| EPS Diluted | 0.84 | 0.34 | 0.074 | 0.35 |
| % Growth | 147.1% | 362% | -79% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |